Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Pancreatic Cancer. 7 results shown below.

S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

[Complete title: S1313, A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 9118
Phase: I/II

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) (apact)

[Complete title: A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 20140859
Phase: III

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

[Complete title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)]
Principal Investigator: Gabriela Chiorean
Study Number: 20141052
Phase: III

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT®-1)

[Complete title: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)]
Principal Investigator: Andrew Coveler, MD
Study Number: 20151371
Phase: III

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)

[Complete title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer (WIRB HALO-109-202)]
Principal Investigator: Sunil Hingorani, MD, PhD
Study Number: 2687.00
Phase: II

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

[Complete title: A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute - Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 8028
Phase: III

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials